HERON THERAPEUTICS, INC. /DE/ Net Change in Cash
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Net Change in Cash of -$7.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-10
- HERON THERAPEUTICS, INC. /DE/ cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$2.53M.
- HERON THERAPEUTICS, INC. /DE/ cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$6.53M.
- HERON THERAPEUTICS, INC. /DE/ cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$8.23M, a 170.16% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $11.73M.
- HERON THERAPEUTICS, INC. /DE/ cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $2.85M.
- HERON THERAPEUTICS, INC. /DE/ cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$2.88M, a 121.60% decline from fiscal 2023.
- HERON THERAPEUTICS, INC. /DE/ cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $13.31M.
- HERON THERAPEUTICS, INC. /DE/ cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$75.18M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.93M 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | -$2.53M 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $2.85M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $17.27M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | -$9.29M 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | -$6.53M 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$2.88M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$2.94M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | -$10.29M 10-Q · filed 2025-08-08 | |||
| 2024-03-31 | -$8.23M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $13.31M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $19.50M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$1.90M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $11.73M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$75.18M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$40.10M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$41.93M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$33.63M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$14.60M 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $54.43M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $86.03M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$45.40M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $33.24M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $23.24M 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $8.83M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $31.39M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $40.06M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $28.27M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $21.20M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | -$8.38M 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | -$112.75M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | -$90.65M 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $131.17M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |